? INDUSTRY STRUCTURE AND DEVELOPMENTS
Global Pharmaceutical Industry Overview
The global pharmaceutical industry continues to remain an important and strategically significant sector, supported by increasing healthcare expenditure, growing access to healthcare, demographic changes, rising prevalence of chronic and lifestyle-related diseases and continued advancement in pharmaceutical research and drug delivery technologies.
The industry encompasses a wide range of activities including pharmaceutical research and development, formulation development, manufacturing, contract manufacturing, generic medicines, specialty formulations, pharmaceutical distribution and healthcare services. Increasing demand for affordable, quality-assured medicines has continued to support the growth of generic pharmaceutical products across developed and emerging markets.
The global pharmaceutical manufacturing landscape is also witnessing a growing preference for outsourcing and strategic partnerships. Pharmaceutical companies are increasingly engaging Contract Manufacturing Organizations (CMOs), Contract Development and Manufacturing Organizations (CDMOs) and other specialised manufacturing partners to optimise manufacturing costs, improve supply-chain flexibility and focus internal resources on research, product development, marketing and distribution.
The demand for pharmaceutical formulations is supported by the increasing burden of chronic diseases, growing healthcare awareness and expansion of healthcare infrastructure, particularly across emerging markets. At the same time, pharmaceutical companies are placing greater emphasis on manufacturing quality, regulatory compliance, product consistency and reliable supply chains.
During FY 2025-26, the global pharmaceutical industry continued to operate in a complex environment characterised by geopolitical uncertainties, changing regulatory requirements, fluctuations in raw material prices, supply-chain considerations and varying market demand across geographies. Despite these near-term challenges, the long-term outlook for the pharmaceutical industry remains favourable, supported by increasing healthcare needs, demand for affordable medicines and continued expansion of pharmaceutical markets globally.
Indian Pharmaceutical Industry
India continues to occupy an important position in the global pharmaceutical industry and has established itself as a major manufacturing base for generic medicines and pharmaceutical formulations. The countrys established pharmaceutical ecosystem, availability of skilled manpower, cost-effective manufacturing capabilities and growing technical expertise provide a strong foundation for continued sectoral development.
The Indian pharmaceutical industry caters to a large and diverse domestic market while also serving customers across international markets. Indian manufacturers participate across several segments including generic formulations, contract manufacturing, active pharmaceutical ingredients, specialty products, branded generics and pharmaceutical exports.
The increasing demand for affordable healthcare, expansion of healthcare infrastructure, growing healthcare awareness and rising prevalence of chronic diseases are expected to support the long-term growth of the Indian pharmaceutical market.
The pharmaceutical manufacturing sector is also witnessing increasing emphasis on quality systems, regulatory compliance, documentation, traceability and Good Manufacturing Practices. These developments are expected to favour organised manufacturers with established infrastructure, quality-control systems and regulatory capabilities.
Indias growing role in global pharmaceutical supply chains also provides opportunities for Indian manufacturers to expand their presence in emerging international markets and establish long-term relationships with pharmaceutical marketers, distributors and institutional customers.
Companys Position in the Industry
Curis Lifesciences Limited (Curis or the Company) is engaged in the development, manufacturing and distribution of pharmaceutical products catering to various therapeutic categories and healthcare requirements. The Companys operations encompass formulation development, pharmaceutical manufacturing and customer- focused solutions, supported by quality assurance and regulatory capabilities.
The Companys business model includes manufacturing pharmaceutical products for domestic and international markets through loan licensing, contract manufacturing and own-brand marketing arrangements . The Company follows a customer-focused and order-driven approach, enabling it to manufacture products according to customer requirements while maintaining focus on quality, consistency and timely delivery.
Curis operates its manufacturing facility at Sanand GIDC-II, Ahmedabad, Gujarat , which is located within an established pharmaceutical and industrial ecosystem. The strategic location provides access to supporting infrastructure, raw material suppliers, skilled manpower, transportation networks and other ancillary services required for pharmaceutical manufacturing operations.
The Companys product portfolio covers a wide range of pharmaceutical dosage forms, including tablets, capsules, liquid orals, external preparations such as creams, gels and ointments, and sterile ophthalmic ointments . The
Companys manufacturing and product capabilities are supported by dedicated production infrastructure and quality- control systems.
The Company also undertakes formulation and development activities through its R&D and formulation development capabilities. Its formulation and development activities cover oral solids, liquid orals and ointments, while its manufacturing processes include wet granulation, dry granulation, compression, coating and filling operations, subject to applicable product and process requirements
The Company also undertakes formulation and development activities through its R&D and formulation development capabilities. Its formulation and development activities cover oral solids, liquid orals and ointments, while its manufacturing processes include wet granulation, dry granulation, compression, coating and filling operations.
As disclosed in the Companys Prospectus, Curis has a broad product portfolio comprising 943 approved products , including 745 products under manufacturing licence G/25/2225 and 198 products under manufacturing licence G/28/1632. This broad product portfolio enables the Company to cater to diverse customer requirements and therapeutic applications.
The Companys quality systems form an important part of its operations. Its quality-control and quality-assurance functions cover raw material testing, microbiological analysis, physical and chemical testing, instrument analysis, process validation, equipment qualification, documentation and in-process quality assurance.
Curis has also developed capabilities to serve international markets. The Company has undertaken direct export activities and has established regulatory and market presence in selected international markets. The Companys international registrations and approvals include markets such as Yemen, Kenya, the Philippines and Nigeria, subject to applicable product and regulatory approvals.
Curis has also developed capabilities to serve international markets. The Company has undertaken direct export activities and has established regulatory and market presence in selected international markets . The Companys international registrations and approvals include markets such as Yemen, Kenya, the Philippines and Nigeria, subject to applicable product registrations and regulatory approvals .
The Companys strategy is focused on leveraging its manufacturing infrastructure, product portfolio, formulation capabilities, quality systems and customer relationships to strengthen its presence in both domestic and international pharmaceutical markets.
During the year under review, Curis Lifesciences Limited (Curis or the Company) , in collaboration with M/s. Eurosun Pharmaceuticals (Eurosun) , entered into a Joint Venture Agreement for establishing and developing a pharmaceutical business in the Federal Republic of Nigeria .
Pursuant to the said arrangement, Curis and Eurosun have jointly established Curosan Pharmaceuticals in Nigeria as a joint venture entity, with the objective of undertaking the registration, marketing, distribution and sale of pharmaceutical products in the Nigerian market.
The joint venture is intended to leverage the respective capabilities of the parties, with Curis contributing its expertise in pharmaceutical product development, formulation, manufacturing and supply, and Eurosun contributing its experience in the Nigerian market, including regulatory coordination, product registration, market development, marketing and distribution.
The principal objective of the joint venture is to facilitate the registration and commercialisation of the Companys pharmaceutical products in Nigeria and to develop the Companys own-brand pharmaceutical business in the Nigerian market, subject to obtaining the requisite regulatory approvals.
The Joint Venture Agreement was approved by the Board of Directors at its meeting held on 24 December 2025 , and the requisite disclosure was made to the National Stock Exchange of India Limited in accordance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 .
During the year under review, the Company and its joint venture partner progressed with the regulatory and product registration process in Nigeria. The Company proposes to commercialise its pharmaceutical products in the Nigerian market upon obtaining the requisite regulatory approvals and fulfilment of applicable statutory and regulatory requirements.
After the closure of the year, on 13 th August, 2026, the Company has made a investment in Curosun Pharmaceutical Nig Ltd (the Investee Company), a company incorporated in Nigeria, by acquiring Ordinary shares equivalent to 49.95% of the Investee Company
The joint venture represents a strategic initiative of the Company to establish a stronger and sustainable presence in Nigeria by combining Curiss pharmaceutical manufacturing and product capabilities with Eurosuns local market and distribution expertise.
During FY 2025-26, the Company delivered a strong financial performance despite a challenging environment:
| Particulars | FY 2025-2026 | FY 2024-2025 | Growth |
| Revenue from Operations (^ Lakhs) | 6062.88 | 5025.86 | 20.63% |
| Profit After Tax (^ Lakhs) | 691.63 | 620.64 | 11.44% |
| Net Worth (^ Lakhs) | 4,735.77 | 1,651.77 | 186.74% |
During FY 2025-26, the Company delivered a healthy financial performance despite a challenging operating environment.
The Companys growth in revenue and profitability reflects increased business activity, operational efficiency and continued focus on cost management . The increase in net worth reflects the strengthening of the Companys equity base during the year, including the impact of the IPO, together with accretion of profits .
Industry Challenges
The pharmaceutical manufacturing industry continues to operate in a highly competitive and regulated environment and is exposed to several operational, financial and market-related challenges, including:
^ Volatility in prices and availability of Active Pharmaceutical Ingredients (APIs), excipients, packaging materials and other raw materials.
^ Increasing regulatory requirements relating to pharmaceutical manufacturing, quality systems, documentation and product approvals.
^ Intense competition in contract manufacturing, loan licensing, generic formulations and branded pharmaceutical markets.
^ Changes in customer procurement strategies, order volumes and outsourcing arrangements.
^ Foreign exchange fluctuations and geopolitical uncertainties affecting international business.
^ Supply-chain disruptions and fluctuations in logistics and freight costs.
^ Increasing requirements for product registrations and regulatory approvals in international markets.
^ Need for continuous investment in manufacturing infrastructure, technology, quality systems and regulatory compliance.
The Company continuously monitors these factors and seeks to mitigate associated risks through prudent procurement practices, inventory management, quality-control systems, operational planning, customer engagement and disciplined financial management.
Industry Opportunities
The Company believes that the long-term fundamentals of the pharmaceutical manufacturing industry remain favourable. Key opportunities available to the Company include:
^ Increasing demand for affordable and quality-assured generic pharmaceutical formulations.
^ Growing outsourcing of pharmaceutical manufacturing by pharmaceutical companies seeking manufacturing flexibility and cost optimisation.
^ Increasing opportunities in contract manufacturing and loan-licensing arrangements.
^ Expansion of pharmaceutical markets across emerging economies.
^ Opportunities to expand direct exports and strengthen international product registrations.
^ Increasing demand for specialised dosage forms and differentiated pharmaceutical formulations.
^ Opportunities arising from the Companys formulation development, quality assurance and regulatory support capabilities.
^ Expansion of the domestic branded pharmaceutical business through the Companys strategic initiatives, including its investment in Uninova Lifesciences Private Limited.
^ Increasing demand for sterile ophthalmic products and other specialised formulations where regulatory-compliant manufacturing capabilities are important.
^ Expansion in the Nigerian pharmaceutical market through the Companys joint venture entity, Curosun Pharmaceutical Nig Ltd., established in collaboration with M/s. Eurosun Pharmaceuticals.
Strengthening of the Companys presence in international markets through strategic business arrangements, including the establishment of Curosun Pharmaceutical Nig Ltd. as a joint venture with M/s. Eurosun Pharmaceuticals in Nigeria.
With its diversified dosage-form capabilities, manufacturing infrastructure, formulation and development capabilities, quality systems and domestic and international market presence, the Company remains focused on capitalising on these opportunities and creating sustainable long-term value for its stakeholders.
* BUSINESS OVERVIEW:
Curis Lifesciences Limited is a pharmaceutical company engaged in the development, manufacturing and distribution of pharmaceutical products across various therapeutic categories. The Company provides formulation and development services and manufactures a diverse range of dosage forms for domestic and international customers.
The Companys product portfolio includes tablets, capsules, liquid orals, external preparations such as creams, gels and ointments, and sterile ophthalmic ointments . These products cater to diverse healthcare requirements across multiple therapeutic categories.
The Company operates a customer-focused and order-driven business model, with activities spanning contract manufacturing, loan licensing and own-brand marketing. The Companys manufacturing capabilities enable it to support customers requiring customised pharmaceutical formulations and manufacturing solutions.
Curiss manufacturing facility is located at Sanand GIDC-II, Ahmedabad, Gujarat. The facility includes production infrastructure and supporting quality-control and quality-assurance systems. The Company has developed manufacturing capabilities across oral solid, oral liquid, external and sterile ophthalmic dosage forms.
The Companys formulation and development capabilities further strengthen its ability to work with customers from product development through manufacturing. Its R&D activities include formulation development for oral solids, liquid orals and ointments, supported by manufacturing process capabilities including wet granulation, dry granulation, compression, coating and filling.
The Company also maintains an international orientation through its export activities and regulatory registrations in selected overseas markets. Its international business provides an opportunity to diversify its revenue base and participate in the growing demand for affordable pharmaceutical products in emerging markets.
Financial And Operational Performance
During FY 2025-26, the Company delivered healthy growth in revenue and profitability despite a challenging operating environment.
| Particulars | Current Year 31.03.2026 | Previous Year 31.03.2025 |
| Revenue from Operations | 6062.88 | 5025.86 |
| Other Income | 28.15 | 1.23 |
| T otal Revenue | 6091.04 | 5027.08 |
| Total Expenditure (Including Depreciation) | 5133.41 | 4129.52 |
| Profit Before Tax before exceptional and extraordinary items and tax | 957.63 | 897.57 |
| Less: Exceptional items {Prior Year Expenses/(Income)(net)} | 1.47 | (1.24) |
| Profit / (Loss) before extraordinary items and tax | 956.16 | 898.81 |
| Less: Extraordinary items | -- | -- |
| Profit Before T ax | 956.16 | 898.81 |
| Less: Tax expense: | ||
| Current tax | 250.00 | 220.00 |
| Deferred tax | 1.24 | 54.68 |
| Shortfall of earlier years tax provision | 13.29 | 3.47 |
| Profit after Tax | 691.63 | 620.64 |
| Earnings Per Share (Basic) | 37.14 | 33.50 |
| Earnings Per Share (Diluted)) | 37.14 | 33.50 |
The Companys audited financial results report revenue from operations of ^6,062.88 Lakh for FY 2025-26 compared with ^ 5,025.86 Lakh in FY 2024-25. Profit after tax increased to ^691.63 Lakh from ^620.64 Lakh during the corresponding period.
The Company achieved Revenue from Operations of ^6,062.88 lakh , registering a growth of 20.63% over the previous financial year. The growth reflects the Companys continued business expansion, increased operating activity and contribution from its domestic and international business initiatives.
Profit After Tax increased to ^691.63 lakh from ^620.64 lakh , representing a growth of 11.44% . The improvement in profitability reflects the Companys continued focus on operational efficiency, cost management and business growth.
The Companys Net Worth increased to ^4,735.77 Lakh as at 31 March 2026 from ^1,651.77 Lakh as at 31 March 2025. The significant increase in net worth reflects the strengthening of the Companys capital base during the year together with the accretion of profits.
Operational Performance
Operational excellence continued to remain an important focus area for the Company during FY 2025-26. The Company continued to focus on improving manufacturing efficiency, optimising resource utilisation, strengthening quality systems and servicing customer requirements.
The Companys diversified dosage-form capabilities across tablets, capsules, oral liquids, external preparations and sterile ophthalmic ointments provide flexibility in addressing different customer requirements.
Continuous emphasis on quality control, procurement planning, inventory management and process improvement enabled the Company to support its manufacturing operations while maintaining the required quality standards.
The Company also continued to focus on expanding its domestic and international business opportunities through customer development, export initiatives and strategic business arrangements.
Outlook
The management remains positive about the long-term prospects of the pharmaceutical manufacturing industry. Increasing healthcare requirements, demand for affordable medicines, growth in generic pharmaceuticals and increasing outsourcing of manufacturing activities are expected to provide opportunities for the Company.
The Company will continue to focus on strengthening its manufacturing capabilities, improving operational efficiency, expanding its customer base and developing domestic and international market opportunities.
The Companys strategic priorities include:
^ Strengthening domestic pharmaceutical manufacturing and customer relationships.
^ Expanding contract manufacturing and loan-licensing opportunities.
^ Increasing utilisation of existing manufacturing capabilities.
^ Strengthening formulation development and product capabilities.
^ Expanding international business and product registrations.
^ Developing the Companys presence in African and other emerging pharmaceutical markets.
^ Developing and expanding the Companys presence in Nigeria through Curosun Pharmaceutical Nig Ltd., its joint venture entity established in collaboration with M/s. Eurosun Pharmaceuticals.
^ Integrating and developing the business opportunities arising from the Uninova investment.
^ Maintaining strong quality, regulatory and compliance standards.
^ Maintaining financial discipline and efficient working-capital management.
* RISKS AND CONCERNS
The Company operates in a dynamic and highly regulated business environment and is exposed to various strategic, operational and financial risks that may affect its business performance.
Raw Material and API Price Risk
APIs, excipients, packaging materials and other raw materials constitute important inputs for the Companys manufacturing operations. Fluctuations in the prices and availability of these materials may affect manufacturing costs, margins and working-capital requirements.
The Company seeks to manage this risk through prudent procurement practices, supplier relationships, inventory planning and continuous monitoring of market conditions.
Regulatory and Compliance Risk
The pharmaceutical industry is subject to stringent regulatory requirements relating to manufacturing, product quality, documentation, approvals and distribution.
Any failure to comply with applicable regulatory requirements or changes in regulatory standards could adversely affect the Companys operations.
The Company maintains quality-control and quality-assurance systems and monitors applicable regulatory requirements to support continued compliance.
Customer Concentration Risk
The Companys business includes contract manufacturing and loan-licensing arrangements with pharmaceutical customers. Changes in customer procurement strategies, order volumes or outsourcing arrangements may affect business volumes and capacity utilisation.
The Company seeks to mitigate this risk by developing relationships with multiple customers and expanding its domestic and international market presence.
Competition Risk
The pharmaceutical manufacturing sector is competitive, with several domestic and international manufacturers operating across generic formulations, contract manufacturing and branded pharmaceutical markets.
The Company seeks to compete through manufacturing capabilities, quality standards, product range, customer service and operational efficiency.
Operational Risk
The Companys manufacturing activities are exposed to risks arising from equipment breakdowns, utility interruptions, quality issues, supply-chain disruptions and availability of skilled personnel.
The Company focuses on preventive maintenance, quality-control procedures, operational planning and safety measures to minimise operational disruptions.
Export and Foreign Exchange Risk
The Companys international business is exposed to foreign exchange fluctuations, geopolitical developments, regulatory requirements and changes in demand in overseas markets.
The Company monitors international market conditions and foreign exchange movements and adopts appropriate commercial strategies to manage these risks.
International Market Risk
The Companys international expansion initiatives, including its joint venture with M/s. Eurosun Pharmaceuticals through Curosun Pharmaceutical Nig Ltd. in Nigeria, are subject to risks associated with regulatory approvals, product registrations, market development, customer demand, foreign exchange movements and the operating environment in overseas markets.
The Company will continue to monitor these developments and work with its business partners to manage operational and commercial risks.
Integration Risk
The Companys strategic initiatives, including its investment in Uninova Lifesciences Private Limited and its joint venture arrangement with M/s. Eurosun Pharmaceuticals through Curosun Pharmaceutical Nig Ltd., involve risks
associated with integration of business operations, product portfolios, marketing activities, regulatory requirements and distribution capabilities.
The Company intends to focus on effective coordination with its joint venture and strategic business partners, regulatory compliance, business integration and commercial development to realise the expected strategic benefits of these initiatives.
? INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY
The Company has established an adequate system of internal controls commensurate with the nature, size and complexity of its business operations. The internal control framework is designed to safeguard the Companys assets, ensure the accuracy and reliability of financial reporting, promote operational efficiency and support compliance with applicable laws, regulations and internal policies.
The internal control framework covers key business processes including procurement, production, inventory management, sales, finance, accounting and statutory compliances.
The Companys internal controls are periodically reviewed by the Internal Auditors. The observations and recommendations arising from such reviews are placed before the Audit Committee, which reviews the adequacy and effectiveness of the internal control environment and monitors implementation of corrective actions wherever required.
The management believes that the Companys existing internal control systems are adequate and commensurate with the size and nature of its operations.
? HUMAN RESOURCES AND INDUSTRIAL RELATIONS
The Company recognises its employees as an important contributor to its continued growth and operational performance. The Company remains focused on developing a work environment that encourages professionalism, teamwork, accountability, learning and continuous improvement.
The Company continues to focus on employee development, skill enhancement, workplace safety and employee welfare. Appropriate emphasis is placed on maintaining a healthy and productive working environment.
Number Of Employees As On 31 st March 2026 - 86 Employees
Industrial relations remained cordial during the year under review, and the Company did not experience any material industrial dispute or disruption affecting its operations.
? KEY FINANCIAL RATIOS
The key financial ratios of the Company are presented in the table below:
| Sr. No. | Ratio | For the year ended 31 March, 2026 | For the year ended 31 March, 2025 | % Variance | Reason for Variance (mandatory if variance exceeds 25%) |
| 1 | Current Ratio | 2.52 | 1.80 | 39.94% | Due to increase in advances and surplus funds from IPO proceeds outstripping the growth in Current Liabilities. |
| 2 | Debt Equity Ratio | 0.12 | 0.45 | -74.05% | Due to repayment of all long-term secured loans and increase in equity base from IPO proceeds. |
| 3 | Debt Service Coverage Ratio | 2.84 | 4.18 | -32.04% | Earnings are same as previous year, but there is an increase in repayment of all secured long-term borrowings from bank from IPO proceeds. |
| 4 | Return on Equity Ratio (%) | 14.60% | 37.57% | -61.13% | Due to increase in denominator by issue of new shares via IPO during the year. |
| 5 | Inventory Turnover Ratio (times and days) | 1.72 times | 2.47 times | -30.22% | Due to increase in closing stock in hand at year end. |
| 211.91 days | 147.87 days | 43.31% | Due to increase in closing stock in hand at year end. | ||
| 6 | Trade Receivable Ratio | 6.45 | 5.70 | 13.02% | -- |
| 7 | Trade Payable Ratio | 13.23 | 13.71 | -3.52% | -- |
| 8 | Net Capital Ratio | 1.45 | 3.60 | -59.64% | Due to increase in capital base from increase in equity base from IPO. |
| 9 | Net Profit Ratio | 11.35% | 12.35% | -8.03% | -- |
| 10 | Return on Capital Employed | 14.00% | 25.25% | -44.57% | Due to increase in equity base. |
| 11 | Return on Investment | 1.51% | 0.52% | 189.04% | Due to increase in interest income on new FDRs created temporarily from surplus funds raised in IPO proceeds. |
The above ratios have been computed in accordance with the applicable Guidance Note on Financial Statements issued by the Institute of Chartered Accountants of India. Explanations for changes of 25% or more , wherever applicable, shall be provided in accordance with the requirements of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
? FUTURE STRATEGY AND OUTLOOK
The long-term outlook for the pharmaceutical manufacturing industry remains favourable, supported by increasing healthcare requirements, demand for affordable medicines, growth in generic pharmaceutical products and increasing outsourcing of manufacturing activities.
Curis Lifesciences Limited remains focused on leveraging its manufacturing infrastructure, formulation capabilities, quality systems and customer relationships to strengthen its position in the pharmaceutical industry.
The Companys strategic priorities include:
^ Strengthening its domestic pharmaceutical manufacturing business.
^ Expanding contract manufacturing and loan-licensing opportunities.
^ Improving manufacturing efficiency and capacity utilisation.
^ Expanding the Companys formulation and product portfolio.
^ Strengthening formulation development and R&D capabilities.
^ Expanding international product registrations and export markets.
^ Strengthening the Companys presence in other emerging international markets.
^ Developing and expanding the Nigerian pharmaceutical market through Curosun Pharmaceutical Nig Ltd., the Companys joint venture entity established in collaboration with M/s. Eurosun Pharmaceuticals.
^ Leveraging potential synergies from the Companys strategic investment in Uninova Lifesciences Private Limited.
^ Strengthening customer relationships and expanding the customer base.
^ Maintaining prudent financial management and efficient working-capital utilisation.
^ Upholding high standards of quality, regulatory compliance, corporate governance and business ethics.
With its diversified pharmaceutical capabilities, manufacturing infrastructure, customer-focused approach and expanding domestic and international opportunities, the Company remains focused on creating sustainable long-term value for its stakeholders.
? CAUTIONARY STATEMENT
Statements in this Management Discussion and Analysis describing the Companys objectives, estimates, expectations, projections, outlook or predictions may constitute forward-looking statements within the meaning of applicable securities laws and regulations.
These statements are based on certain assumptions and expectations regarding future events and involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied in such forwardlooking statements due to various factors, including changes in economic conditions, government policies, healthcare and pharmaceutical market conditions, raw material prices, foreign exchange fluctuations, competition, regulatory developments, customer demand, supply-chain disruptions and other factors beyond the Companys control.
The Company does not undertake any obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as may be required under applicable laws and regulations.
? SEGMENT-WISE AND PRODUCT-WISE PERFORMANCE
During the financial year under review, the Company continued to operate in a single business segment, i.e. manufacturing of pharmaceutical products. The Company is engaged in the manufacture of various pharmaceutical formulations, primarily comprising tablets, capsules, oral liquids, external preparations and sterile ophthalmic ointments. Accordingly, there is no separate reportable business segment requiring disclosure.
During FY 2025-26, the Company recorded revenue from operations of approximately ^6062.88 Lakhs as compared with approximately ^5025.86 Lakhs in FY 2024-25, representing growth of approximately 20.63%.
The Companys product portfolio comprises the following major categories:
| PRODUCT CATEGORY | PERFORMANCE DURING FY 2025-26 |
| Tablets | Continued to remain one of the key products in the Company\u2019s portfolio and contributed significantly to overall business performance. |
| Capsules | The Company continued to manufacture capsules for its customers, with the product category supporting the overall growth of the business |
| Oral Liquids | The Company continued its manufacturing activities in oral liquid formulations, catering to the requirements of its customers. |
| External Preparations | The Company manufactures external preparations such as creams, gels and ointments and continued to serve customer requirements during the year. |
| Sterile Ophthalmic Ointments | The Company continued manufacturing sterile ophthalmic ointments as part of its diversified pharmaceutical product portfolio. |
The Companys diversified product portfolio enables it to cater to different requirements of pharmaceutical customers and provides flexibility in terms of production and capacity utilisation. The Company has manufacturing capabilities across different dosage forms, including tablets, capsules, oral liquids, external preparations and sterile ophthalmic ointments.
The Companys joint venture initiative in Nigeria through Curosun Pharmaceutical Nig Ltd. is expected to provide an additional platform for expanding the Companys international pharmaceutical business and accessing the growing African pharmaceutical market.
DATE: 07/09/2026 PLACE: SANAND
FOR CURIS LIFESCIENCES LIMITED
| sd/- | sd/- |
| (SIGNATURE) | (SIGNATURE) |
| JAIMIK MANSUKHLAL PATEL | DHARMESH DASHARATHBHAI PATEL |
| WHOLE-TIME DIRECTOR | MANAGING DIRECTOR AND CHAIRMAN |
| DIN: 07371003 | DIN: 07371033 |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.